Umbralisib
Umbralisib is a targeted cancer medication that works by inhibiting the PI3K-delta enzyme, which plays a key role in the growth and survival of certain cancer cells. It is primarily used to treat adults with relapsed or refractory marginal zone lymphoma and follicular lymphoma who have received at least prior therapy. This oral medication represents a treatment option for patients with these types of non-Hodgkin lymphomas.
Umbralisib is an oral PI3K-delta inhibitor used to treat certain relapsed or refractory B-cell lymphomas including marginal zone lymphoma and follicular lymphoma.
Key facts at a glance
- ATC
- L01EX25
- RxNorm
- 2478439
- Generic
- Umbralisib
- Class
- atc-l01
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- tablet
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Umbralisib is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) and relapsed or refractory follicular lymphoma (FL) who have received at least one prior anti-CD20-based regimen.
Umbralisib is a phosphoinositide 3-kinase (PI3K) delta inhibitor. It works by blocking the PI3K-delta pathway, which is involved in the proliferation, survival, and migration of malignant B-cells. By inhibiting this signaling pathway, the drug helps control the growth and spread of cancer cells.
Common side effects include diarrhea, fatigue, nausea, and liver enzyme elevations. It carries a FDA Boxed Warning for hepatotoxicity and serious diarrhea/colitis. Patients require regular monitoring of liver function tests. May increase risk of infections and should be used with caution in patients with underlying immune system disorders. Drug interactions may occur with strong CYP3A4 inducers and inhibitors.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy